Author: US WorldMeds

HCM & HRIS

US WorldMeds® Receives Full U.S. FDA Approval of TECELRA® (afamitresgene autoleucel) with an Expanded Indication, Extending the First Approved Engineered T-Cell Therapy for a Solid Tumor to Children as Young as 12

July 2, 2026
US WorldMeds
No Comments

Eligibility extends to patients with unresectable or metastatic synovial sarcoma who have received prior chemotherapy and…